OBJECTIVE： To investigate the effects of simvastatin on neurologic function and prognosis of patients with cerebral infraction. METHODS： A total of 82 patients with cerebral infarction selected from our hospital during Jan. 2015 to Jul. 2016 were divided into observation group and control group according to random number table， with 41 cases in each group. Control group received routine thrombolytic therapy and Aspirin enteric-coated tablets 100 mg orally， qd. Observation group was additionally given Simvastatin tablets 10 mg， qd， on the basis of control group. After 1 month of treatment， prognosis， ADE as well as NIHSS scores before and after treatment were compared between 2 groups. Multiple factor Logistic regression analysis was conducted for clinical information of patients. RESULTS： The excellent rate of prognosis in observation group was 80.49％， which was significantly higher than 68.29％， with statistical significance （P＜0.05）. The incidence of intracranial and extracranial vascular stenosis， brain-heart syndrome and death in observation group were 36.59％， 19.51％， 0， which were significantly lower than 46.34％， 36.59％， 7.32％ of control group， with statistical significance （P＜0.05）. At admission， there was no statistical significance in NIHSS scores between 2 groups （P＞0.05）. After 1 month of treatment， NIHSS scores of 2 groups were decreased significantly， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. Age ＞65 years， NIHSS score ＜4 points at admission， combined diabetes， non-use of statins were independent risk factors which affected the survival of patients with cerebral infarction （P＜0.05）.  CONCLUSIONS： Simvastatin can significantly improve the neurologic function and prognosis of patients with cerebral infarction， and reduce the incidence of ADE. Non-use of statins is an independent risk factor which affects the survival of patients.